Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.40
-0.12-3.41%
At close: -
$3.40
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Design Therapeutics Analyst Ratings and Price Targets | NASDAQ:DSGN | Benzinga
Design Therapeutics Inc has a consensus price target of $6.75 based on the ratings of 5 analysts. The high is $12 issued by Piper Sandler on May 7, 2024. The low is $4 issued by RBC Capital on August 6, 2024. The 3 most-recent analyst ratings were released by RBC Capital, Piper Sandler, and RBC Capital on August 6, 2024, May 7, 2024, and March 20, 2024, respectively. With an average price target of $6.67 between RBC Capital, Piper Sandler, and RBC Capital, there's an implied 96.08% upside for Design Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Piper Sandler
Wedbush
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Design Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 08/06/2024 | Buy Now | 17.65% | RBC Capital | Leonid Timashev37% | $4 → $4 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 05/07/2024 | Buy Now | 252.94% | Piper Sandler | Yasmeen Rahimi56% | $6 → $12 | Upgrade | Neutral → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 17.65% | RBC Capital | Leonid Timashev37% | $4 → $4 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/20/2024 | Buy Now | 47.06% | Wedbush | Laura Chico44% | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 11/14/2023 | Buy Now | 17.65% | RBC Capital | Leonid Timashev37% | $7 → $4 | Maintains | Sector Perform | Get Alert |
| 08/15/2023 | Buy Now | 76.47% | Wedbush | Laura Chico44% | → $6 | Downgrade | Outperform → Neutral | Get Alert |
| 08/15/2023 | Buy Now | 76.47% | SVB Leerink | Joseph Schwartz65% | → $6 | Downgrade | Outperform → Market Perform | Get Alert |
| 08/15/2023 | Buy Now | 105.88% | RBC Capital | Leonid Timashev37% | $23 → $7 | Downgrade | Outperform → Sector Perform | Get Alert |
| 05/10/2023 | Buy Now | 576.47% | RBC Capital | Leonid Timashev37% | $24 → $23 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | 458.82% | Wedbush | Laura Chico44% | $20 → $19 | Maintains | Outperform | Get Alert |
| 05/04/2023 | Buy Now | — | Goldman Sachs | Madhu Kumar73% | — | Upgrade | Sell → Neutral | Get Alert |
| 03/15/2023 | Buy Now | 605.88% | RBC Capital | Leonid Timashev37% | → $24 | Reiterates | → Outperform | Get Alert |
| 12/09/2022 | Buy Now | 547.06% | SVB Leerink | Joseph Schwartz65% | $30 → $22 | Maintains | Outperform | Get Alert |
| 12/08/2022 | Buy Now | 605.88% | RBC Capital | Leonid Timashev37% | $29 → $24 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | 664.71% | Wedbush | Laura Chico44% | $21 → $26 | Maintains | Outperform | Get Alert |
| 06/10/2022 | Buy Now | 517.65% | Wedbush | Laura Chico44% | → $21 | Initiates | → Outperform | Get Alert |
| 05/24/2022 | Buy Now | 76.47% | Goldman Sachs | Madhu Kumar73% | $8 → $6 | Maintains | Sell | Get Alert |
| 05/10/2022 | Buy Now | 782.35% | SVB Leerink | Joseph Schwartz65% | $36 → $30 | Maintains | Outperform | Get Alert |
| 05/02/2022 | Buy Now | 782.35% | RBC Capital | Leonid Timashev37% | → $30 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Design Therapeutics (DSGN) stock?
The latest price target for Design Therapeutics (NASDAQ:DSGN) was reported by RBC Capital on August 6, 2024. The analyst firm set a price target for $4.00 expecting DSGN to rise to within 12 months (a possible 17.65% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Design Therapeutics (DSGN)?
The latest analyst rating for Design Therapeutics (NASDAQ:DSGN) was provided by RBC Capital, and Design Therapeutics reiterated their sector perform rating.
When was the last upgrade for Design Therapeutics (DSGN)?
The last upgrade for Design Therapeutics Inc happened on May 7, 2024 when Piper Sandler raised their price target to $12. Piper Sandler previously had a neutral for Design Therapeutics Inc.
When was the last downgrade for Design Therapeutics (DSGN)?
The last downgrade for Design Therapeutics Inc happened on August 15, 2023 when Wedbush changed their price target from N/A to $6 for Design Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Design Therapeutics (DSGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on August 6, 2024 so you should expect the next rating to be made available sometime around August 6, 2025.
Is the Analyst Rating Design Therapeutics (DSGN) correct?
While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a reiterated with a price target of $4.00 to $4.00. The current price Design Therapeutics (DSGN) is trading at is $3.40, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.